B D Minsky

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation
    J Milburn Jessup
    Department of Oncology, Georgetown University Medical Center, Washington, DC, USA
    JAMA 294:2703-11. 2005
  2. ncbi request reprint Results of local excision followed by postoperative radiation therapy for rectal cancer
    B D Minsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Radiat Oncol Investig 5:246-51. 1997
  3. ncbi request reprint Combined modality therapy of resectable rectal cancer: current approaches
    B D Minsky
    Department of Radiation, Oncology Memorial Sloan Kettering Cancer Center Weill Medical College, Cornell University, 1275 York Avenue, New York, USA
    Tech Coloproctol 8:67-76. 2004
  4. ncbi request reprint Combined-modality therapy of rectal cancer with oxaliplatin-based regimens
    Bruce D Minsky
    Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10021 6007, USA
    Clin Colorectal Cancer 4:S29-36. 2004
  5. ncbi request reprint Combined modality therapy for rectal cancer
    Bruce D Minsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Chemother Biol Response Modif 21:803-16. 2003
  6. ncbi request reprint Adjuvant therapy of resectable rectal cancer
    Bruce D Minsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Treat Rev 28:181-8. 2002
  7. ncbi request reprint Combined-modality therapy of rectal cancer with irinotecan-based regimens
    Bruce D Minsky
    Department of Radiation Oncology, Memorial Sloan Kettering, Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 18:49-55. 2004
  8. ncbi request reprint Adjuvant therapy for rectal cancer--the transatlantic view
    B D Minsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA
    Colorectal Dis 5:416-22. 2003
  9. ncbi request reprint INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy
    Bruce D Minsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:1167-74. 2002
  10. ncbi request reprint Choosing the correct modality for the treatment of dysphagia in the patient with esophageal cancer
    Bruce D Minsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Support Oncol 4:377. 2006

Detail Information

Publications91

  1. ncbi request reprint Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation
    J Milburn Jessup
    Department of Oncology, Georgetown University Medical Center, Washington, DC, USA
    JAMA 294:2703-11. 2005
    ....
  2. ncbi request reprint Results of local excision followed by postoperative radiation therapy for rectal cancer
    B D Minsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Radiat Oncol Investig 5:246-51. 1997
    ..The results of local excision and postoperative RT are encouraging, however, more experience is needed to determine if this approach will have similar local control and survival rates as standard surgery...
  3. ncbi request reprint Combined modality therapy of resectable rectal cancer: current approaches
    B D Minsky
    Department of Radiation, Oncology Memorial Sloan Kettering Cancer Center Weill Medical College, Cornell University, 1275 York Avenue, New York, USA
    Tech Coloproctol 8:67-76. 2004
    ..Regimens using CPT-11 or oxaliplatin-based combined modality therapy plus either continuous infusion 5-FU or capecitibine are under active development...
  4. ncbi request reprint Combined-modality therapy of rectal cancer with oxaliplatin-based regimens
    Bruce D Minsky
    Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10021 6007, USA
    Clin Colorectal Cancer 4:S29-36. 2004
    ..Based on results from phase I/II trials, the recommended regimen for patients who receive oxaliplatin-based combined modality therapy is continuous infusion 5-fluorouracil or capecitabine with pelvic radiation...
  5. ncbi request reprint Combined modality therapy for rectal cancer
    Bruce D Minsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Chemother Biol Response Modif 21:803-16. 2003
  6. ncbi request reprint Adjuvant therapy of resectable rectal cancer
    Bruce D Minsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Treat Rev 28:181-8. 2002
    ..Phase I/II trials examining the use of new chemotherapeutic agents in combination with pelvic radiation therapy are in progress...
  7. ncbi request reprint Combined-modality therapy of rectal cancer with irinotecan-based regimens
    Bruce D Minsky
    Department of Radiation Oncology, Memorial Sloan Kettering, Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 18:49-55. 2004
    ..New trials examining preoperative combined-modality therapy regimens substituting capecitabine (Xeloda) for continuous infusion 5-FU are in progress...
  8. ncbi request reprint Adjuvant therapy for rectal cancer--the transatlantic view
    B D Minsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA
    Colorectal Dis 5:416-22. 2003
    ..Therefore, despite TME surgery, radiation therapy is still a necessary component in the adjuvant management of rectal cancer...
  9. ncbi request reprint INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy
    Bruce D Minsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:1167-74. 2002
    ..To compare the local/regional control, survival, and toxicity of combined-modality therapy using high-dose (64.8 Gy) versus standard-dose (50.4 Gy) radiation therapy for the treatment of patients with esophageal cancer...
  10. ncbi request reprint Choosing the correct modality for the treatment of dysphagia in the patient with esophageal cancer
    Bruce D Minsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Support Oncol 4:377. 2006
  11. ncbi request reprint UFT plus oral leucovorin calcium (Orzel) and radiation in combined modality therapy: a comprehensive review
    B D Minsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 96:1-10. 2001
    ..This paper summarizes the therapeutic rationale for Orzel and reviews the clinical experience with UFT and UFT/LV in combined modality therapy regimens...
  12. ncbi request reprint Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus
    B D Minsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 43:517-23. 1999
    ..To determine the outcome of neoadjuvant chemotherapy followed by concurrent chemotherapy plus high-dose radiation therapy in patients with local/regional squamous cell carcinoma of the esophagus...
  13. ncbi request reprint Radiation therapy for rectosigmoid and rectal cancer: results of the 1992-1994 Patterns of Care process survey
    B D Minsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 16:2542-7. 1998
    ..To determine the US national practice standards for patients with adenocarcinoma of the rectum treated in radiation oncology facilities...
  14. ncbi request reprint Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma
    A Grann
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 49:987-95. 2001
    ..It is an alternative approach for the treatment of uT3 clinically resectable rectal cancer...
  15. ncbi request reprint High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer
    K M Alektiar
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 48:219-26. 2000
    ..This is an update of our preliminary report with longer follow-up and larger patient numbers...
  16. ncbi request reprint Postoperative radiation therapy for rectal cancer combined with UFT/leucovorin
    D I Rosenthal
    Department of Radiation Oncology, University of Pennsylvania Cancer Center, Philadelphia, USA
    Oncology (Williston Park) 14:59-62. 2000
    ..A combination of postoperative adjuvant UFT plus leucovorin concurrent with radiation therapy should be feasible, and the design of an ongoing phase I trial is presented...
  17. ncbi request reprint Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer
    Jose G Guillem
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Am Coll Surg 199:1-7. 2004
    ..Our goal was to determine the prognostic significance of FDG-PET assessment of rectal cancer response to preoperative chemoradiation...
  18. ncbi request reprint Rectus flap reconstruction decreases perineal wound complications after pelvic chemoradiation and surgery: a cohort study
    David B Chessin
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 12:104-10. 2005
    ..Our purpose was to determine the effect of rectus abdominus myocutaneous (RAM) flap reconstruction on perineal wound morbidity in this population...
  19. ncbi request reprint Primary combined-modality therapy for esophageal cancer
    Bruce D Minsky
    Weill Medical College of Cornell University, Department of Radiation Oncology, Memorial Sloan Kettering, Cancer Center, New York, New York, 10021, USA
    Oncology (Williston Park) 20:497-505; discussion 505-6, 511-3. 2006
    ..The addition of surgery following primary combined-modality therapy apparently does not improve survival, but this finding is controversial...
  20. ncbi request reprint Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience
    G Y Ku
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Ann Oncol 19:533-7. 2008
    ..Esophageal small-cell carcinoma (SCC) is rare, highly malignant and the optimal treatment approach has not been defined...
  21. ncbi request reprint Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care Study
    L R Coia
    Department of Radiation Oncology, Community Medical Center, Toms River, NJ 08755, USA
    J Clin Oncol 18:455-62. 2000
    ....
  22. ncbi request reprint A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography
    Francesco Stipa
    Department of Surgery Colorectal Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Room C 1077, New York, New York 10021, USA
    Ann Surg Oncol 13:1047-53. 2006
    ..However, the prognostic significance of pCR remains unclear...
  23. doi request reprint Prognostic implications of the distribution of lymph node metastases in rectal cancer after neoadjuvant chemoradiotherapy
    Tobias Leibold
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room C 1077, New York, NY 10021, USA
    J Clin Oncol 26:2106-11. 2008
    ..The aim of this study was to examine the prognostic significance of location of involved lymph nodes in rectal cancer patients after preoperative chemoradiotherapy...
  24. ncbi request reprint Results after rectal cancer resection with in-continuity partial vaginectomy and total mesorectal excision
    L Ruo
    Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 10:664-8. 2003
    ..Although sharp mesorectal excision reduces circumferential margin involvement and local recurrence, a concomitant partial vaginectomy may be required in women with locally advanced rectal cancer...
  25. pmc Combined modality chemoradiation in elderly oesophageal cancer patients
    S E Anderson
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Br J Cancer 96:1823-7. 2007
    ..Patients with local/regional oesophageal cancer with adequate functional status should not be excluded from potentially curative treatment based on age alone...
  26. ncbi request reprint Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome
    Harvey G Moore
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Room C 1077, New York, NY 10021, USA
    Ann Surg Oncol 11:955-61. 2004
    ..Although numerous studies have focused on identifying molecular markers of prognosis in the primary rectal cancer before CMT, our aim was to identify markers of prognosis in residual rectal cancer after preoperative CMT...
  27. ncbi request reprint Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Am J Surg Pathol 28:215-23. 2004
    ..Our results demonstrate distinct morphologic features in treated rectal carcinomas that are prognostically relevant...
  28. ncbi request reprint Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection
    Harvey G Moore
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Dis Colon Rectum 47:279-86. 2004
    ..Prolongation of the interval between preoperative combined modality therapy and surgery (RT-surgery interval) as a means of increasing pathologic complete response rate has not been fully examined...
  29. ncbi request reprint Combined-modality therapy for rectal cancer using irinotecan
    Bruce D Minsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 16:35-8. 2002
    ..Irinotecan (CPT-11, Camptosar)-based regimens have improved survival in patients with metastatic disease and are being actively investigated in combination with pelvic radiation therapy for patients with rectal cancer...
  30. ncbi request reprint Combined modality therapy in esophageal cancer: the Memorial experience
    Sibyl E Anderson
    Department of Medicine, Gastrointestinal Oncology Service Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and Cornell University Weill Medical College, New York, New York 10021, USA
    Semin Surg Oncol 21:228-32. 2003
    ..The incorporation of these non-5-FU-based therapies with novel biologic agents is planned...
  31. ncbi request reprint Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone
    Aviram Nissan
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:4078-84. 2006
    ..The aim of this study was to identify predictors of recurrence in this group of patients to enhance treatment selection...
  32. ncbi request reprint Squamous-cell carcinoma of the rectum: a rare but curable tumor
    Caio S R Nahas
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Dis Colon Rectum 50:1393-400. 2007
    ..This study was designed to evaluate one institution's experience with treatment outcomes for rectal squamous-cell carcinoma...
  33. ncbi request reprint Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results--Medicare
    D Schrag
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 19:3712-8. 2001
    ..To examine the relationship between patient characteristics and the use of adjuvant pelvic radiation with and without chemotherapy among patients aged 65 years and older with stage II and III rectal cancer...
  34. ncbi request reprint Preoperative radiation with or without chemotherapy and full-thickness transanal excision for selected T2 and T3 distal rectal cancers
    L Ruo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Colorectal Dis 17:54-8. 2002
    ..To evaluate the clinical outcome of selected patients with distal rectal cancer treated by preoperative radiation with or without chemotherapy and full-thickness local excision (FTLE)...
  35. ncbi request reprint Can differences in bowel function after surgery for rectal cancer be identified by the European Organization for Research and Treatment of Cancer quality of life instrument?
    Heather B Neuman
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, New York 10021, USA
    Ann Surg Oncol 14:1727-34. 2007
    ....
  36. ncbi request reprint Oxaliplatin-based combined-modality therapy for rectal cancer
    Bruce D Minsky
    Department of Radiation Oncolgy, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 30:26-33. 2003
    ..In this review, the results of these approaches as well as novel combined-modality approaches using oxaliplatin-based regimens will be presented...
  37. doi request reprint Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation
    Hak Mien Quah
    Department of Colorectal Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 113:57-64. 2008
    ....
  38. ncbi request reprint Oncologic outcomes of salvage surgery for epidermoid carcinoma of the anus initially managed with combined modality therapy
    Robert P Akbari
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Dis Colon Rectum 47:1136-44. 2004
    ..Primary chemoradiation failure for epidermoid carcinoma of the anus is treated by surgical resection. This study evaluates the outcome of salvage surgery at one institution...
  39. doi request reprint Squamous-cell carcinoma of the anal canal: predictors of treatment outcome
    Ramin Roohipour
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Dis Colon Rectum 51:147-53. 2008
    ..The incidence of anal canal squamous-cell carcinoma is increasing. Limited data exist on predictors of treatment failure. This study was designed to identify predictors for relapse/persistence after first-line therapy...
  40. ncbi request reprint Recursive partitioning analysis of pretreatment variables of 416 patients with locoregional esophageal cancer treated with definitive concomitant chemoradiotherapy on Intergroup and Radiation Therapy Oncology Group trials
    Charles R Thomas
    Department of Radiation Oncology, The University of Texas Health Science Center, San Antonio, TX 78229 3900, USA
    Int J Radiat Oncol Biol Phys 58:1405-10. 2004
    ....
  41. ncbi request reprint Conservative management of rectal cancer with local excision and adjuvant therapy
    R T Wagman
    Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, USA
    Oncology (Williston Park) 15:513-9, 524;discussion 524-8. 2001
    ..In summary, the results of local excision and radiation therapy are encouraging. Randomized trials are needed to determine whether this approach has local control and survival rates comparable to those of radical surgery...
  42. pmc Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy
    Leyo Ruo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg 236:75-81. 2002
    ....
  43. ncbi request reprint Ten-year results of preoperative radiation followed by sphincter preservation for rectal cancer: increased local failure rate in nonresponders
    Ramesh Rengan
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Colorectal Cancer 5:413-21. 2006
    ..The primary objective of this study was to determine the long-term outcome of sphincter preservation with preoperative radiation therapy (RT) and surgical resection in the treatment of distal rectal adenocarcinoma...
  44. ncbi request reprint Radiation plus chemotherapy as adjuvant therapy for rectal cancer
    Bruce D Minsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, Cornell University, USA
    Best Pract Res Clin Gastroenterol 16:267-82. 2002
    ..This chapter reviews the rationale and results for neo-adjuvant therapy, the selection process for pre-operative versus post-operative treatment, and new approaches and controversies...
  45. ncbi request reprint Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer
    Matthew S Katz
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 62:1363-70. 2005
    ..To assess whether 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, might enhance the efficacy of neoadjuvant chemoradiation in rectal cancer...
  46. ncbi request reprint Sacral resection for recurrent rectal cancer: analysis of morbidity and treatment results
    Genevieve B Melton
    Division of Colorectal Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Dis Colon Rectum 49:1099-107. 2006
    ..Composite sacropelvic resection for locally advanced recurrent rectal cancer is a high-risk procedure that benefits select patients. We reviewed our recent institutional experience to evaluate case selection, morbidity, and outcomes...
  47. ncbi request reprint Predictors of survival in recurrent rectal cancer after resection and intraoperative radiotherapy
    Margo Shoup
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Dis Colon Rectum 45:585-92. 2002
    ..This study was designed to determine predictors of survival after surgery and intraoperative radiotherapy for recurrent rectal cancer...
  48. doi request reprint Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning
    Jean L Wright
    Department of Radiation Oncology, University of Miami, Miami, FL 33133, USA
    Int J Radiat Oncol Biol Phys 78:1064-72. 2010
    ..To better define the CTV for IMRT, we evaluated patterns and predictors of LRF in SCCAC patients given conventional radiation treatment...
  49. ncbi request reprint A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients
    Harvey G Moore
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Am Coll Surg 197:22-8. 2003
    ....
  50. ncbi request reprint Adequacy of 1-cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined-modality therapy
    Harvey G Moore
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 10:80-5. 2003
    ..To further define the subset of rectal cancer patients suitable for this approach, we determined the adequacy of a distal margin of < or = 1 cm in patients with locally advanced rectal cancer requiring preoperative CMT...
  51. ncbi request reprint Predictive clinicopathologic factors for limited response of T3 rectal cancer to combined modality therapy
    Anne Y Lin
    Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Colorectal Dis 23:243-9. 2008
    ..The aim of this study was to identify pretreatment factors associated with poor tumor response to neoadjuvant chemoradiation...
  52. ncbi request reprint Evaluation of preoperative and postoperative radiotherapy on long-term functional results of straight coloanal anastomosis
    Daniel R Nathanson
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Dis Colon Rectum 46:888-94. 2003
    ....
  53. ncbi request reprint Present indications for adjuvant therapy in resectable rectal cancer
    B D Minsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, Cornell University Medical College-Ittaca, N.Y. 14853, USA
    Ann Ital Chir 72:519-26. 2001
    ..This review examines both the selection criteria and results of adjuvant combined modality therapy for patients with clinically resectable rectal cancer...
  54. pmc Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114)
    Gary K Schwartz
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 27:1956-62. 2009
    ..Toxicity is also significant. More beneficial and safer regimens are needed...
  55. doi request reprint Sphincter preservation in low rectal cancer is facilitated by preoperative chemoradiation and intersphincteric dissection
    Martin R Weiser
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg 249:236-42. 2009
    ....
  56. ncbi request reprint Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients
    Spiros P Hiotis
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10021, USA
    J Am Coll Surg 194:131-5; discussion 135-6. 2002
    ..Some investigators have proposed that such patients should simply be observed and not undergo resection...
  57. pmc A prospective pathologic analysis using whole-mount sections of rectal cancer following preoperative combined modality therapy: implications for sphincter preservation
    Jose G Guillem
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 245:88-93. 2007
    ....
  58. ncbi request reprint Complications after preoperative combined modality therapy and radical resection of locally advanced rectal cancer: a 14-year experience from a specialty service
    David B Chessin
    Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Am Coll Surg 200:876-82; discussion 882-4. 2005
    ..But its impact on postoperative complications has not been adequately evaluated. Our aims were to evaluate our comprehensive experience and identify factors predictive of complications in this patient population...
  59. doi request reprint cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted
    Jose G Guillem
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 26:368-73. 2008
    ..We therefore determined the accuracy of pre-CMT ERUS or magnetic resonance imaging (MRI) staging, to explore the validity of a nonpreoperative CMT approach for cT3N0 disease...
  60. ncbi request reprint Prognostic factors after combined modality treatment of squamous cell carcinoma of the esophagus
    Nabil P Rizk
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Room C 883, New York, NY 10021, USA
    J Thorac Oncol 2:1117-23. 2007
    ..In this study, we evaluated prognostic factors among patients with squamous cell carcinoma (SCC) of the esophagus who have undergone a similar treatment regimen...
  61. ncbi request reprint American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma
    Nabil P Rizk
    Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:507-12. 2007
    ..However, none of these methods has been formally evaluated. The purpose of this study was to establish prognostic pathologic variables after CRT...
  62. ncbi request reprint Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer
    David P Kelsen
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:3719-25. 2007
    ..The relationship between resection type and between tumor response and outcome were also analyzed...
  63. ncbi request reprint Positron emission tomography detection of distant metastatic or synchronous disease in patients with locally advanced rectal cancer receiving preoperative chemoradiation
    Caio S R Nahas
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 15:704-11. 2008
    ....
  64. ncbi request reprint Combined modality therapy for esophageal cancer
    Bruce D Minsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Semin Oncol 30:46-55. 2003
    ..There is considerable controversy as to the ideal therapeutic approach. This review will examine the results of these approaches as well as combined modality therapy using novel regimens...
  65. ncbi request reprint Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial
    Robert J Downey
    Thoracic Service and Gastric and Mixed Tumor Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:428-32. 2003
    ....
  66. pmc Long-term results of local excision for rectal cancer
    Philip B Paty
    Department of Surgery, Pathology, and Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg 236:522-29; discussion 529-30. 2002
    ..To review the authors' experience with local excision of early rectal cancers to assess the effectiveness of initial treatment and of salvage surgery...
  67. ncbi request reprint Surgical salvage of recurrent rectal cancer after transanal excision
    Martin R Weiser
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Dis Colon Rectum 48:1169-75. 2005
    ..This study examines surgical salvage of locally recurrent rectal cancer following transanal excision of early tumors...
  68. pmc Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer
    Jose G Guillem
    Department of Surgery Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg 241:829-36; discussion 836-8. 2005
    ....
  69. ncbi request reprint Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point
    Jose G Guillem
    Colorectal Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room C 1077, New York, NY 10021, USA
    J Clin Oncol 23:3475-9. 2005
    ..However, because the accuracy of this approach has not been established, we conducted a prospective analysis to determine the operating surgeon's ability to assess response using DRE...
  70. ncbi request reprint Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy
    Baruch Brenner
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 22:45-52. 2004
    ..To define the maximum-tolerated dose (MTD) of paclitaxel when given as a weekly 96-hour infusion with cisplatin and radiotherapy for patients with esophageal cancer...
  71. ncbi request reprint Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer
    David H Ilson
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:2926-32. 2003
    ..To identify the maximum-tolerated dose and dose-limiting toxicity (DLT) of weekly irinotecan combined with cisplatin and radiation in esophageal cancer...
  72. ncbi request reprint Distal cT2N0 rectal cancer: is there an alternative to abdominoperineal resection?
    Ramesh Rengan
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 23:4905-12. 2005
    ....
  73. ncbi request reprint The development of a validated instrument to evaluate bowel function after sphincter-preserving surgery for rectal cancer
    Larissa K Temple
    Department of Surgery, Division of Colorectal Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Dis Colon Rectum 48:1353-65. 2005
    ..Therefore, the purpose of this study was to develop an instrument to evaluate bowel function after sphincter-preserving surgery...
  74. ncbi request reprint Prognostic significance of depth of gross or microscopic perirectal fat invasion in T3 N0 M0 rectal cancers following sharp mesorectal excision and no adjuvant therapy
    Antonio I Picon
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY 10021, New York, USA
    Int J Colorectal Dis 18:487-92. 2003
    ..Our aim was to determine the prognostic significance of gross perirectal fat invasion, or depth of microscopic perirectal fat invasion, in T3 N0 rectal cancers following sharp mesorectal excision and no adjuvant therapy...
  75. pmc T1 adenocarcinoma of the rectum: transanal excision or radical surgery?
    David J Bentrem
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 242:472-7; discussion 477-9. 2005
    ..We performed a retrospective evaluation of patients with T1 rectal cancers treated by either transanal excision or radical resection at our institution to assess patient selection, cancer recurrence, and survival...
  76. ncbi request reprint Residual mesorectal lymph node involvement following neoadjuvant combined-modality therapy: rationale for radical resection?
    Francesco Stipa
    Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Ann Surg Oncol 11:187-91. 2004
    ....
  77. ncbi request reprint The national practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996-1999 Patterns of Care Study
    Mohan Suntharalingam
    Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Int J Radiat Oncol Biol Phys 56:981-7. 2003
    ..This study examined the evaluation and treatment schemes used during this time and compared these results to the PCS data obtained between 1992 and 1994 to identify any fundamental changes in national practice...
  78. ncbi request reprint Primary adenocarcinoma of the anus treated with combined modality therapy
    Kathryn P Beal
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Dis Colon Rectum 46:1320-4. 2003
    ..The purpose of this study was to determine the local control and survival of patients with adenocarcinoma of the anus who received combined modality therapy as a component of their treatment...
  79. ncbi request reprint Esophageal cancer phospholipids correlated with histopathologic findings: a 31P NMR study
    T E Merchant
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA
    NMR Biomed 12:184-8. 1999
    ..These data provide a statistical correlation between histopathologic features and molecules known to play an important role in cellular activities and processes unique to malignant tissues...
  80. pmc Multidisciplinary case teams: an approach to the future management of advanced colorectal cancer
    B D Minsky
    The Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Cancer 77:1-4. 1998
    ....
  81. ncbi request reprint Increased endocrine cells in treated rectal adenocarcinomas: a possible reflection of endocrine differentiation in tumor cells induced by chemotherapy and radiotherapy
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Surg Pathol 26:863-72. 2002
    ..The possible mechanism for the increased endocrine cells in treated rectal adenocarcinomas may be related to induction of endocrine differentiation in tumor cells by cytotoxic insult...
  82. ncbi request reprint Colorectal cancer pelvic recurrences: determinants of resectability
    Harvey G Moore
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Dis Colon Rectum 47:1599-606. 2004
    ....
  83. ncbi request reprint Randomized, multicenter, phase IIb study of preoperative chemoradiotherapy in T3 mid-distal rectal cancer: raltitrexed + oxaliplatin + radiotherapy versus cisplatin + 5-fluorouracil + radiotherapy
    Vincenzo Valentini
    Department of Radiation Therapy, Universita Cattolica Sacro Cuore, Rome, Italy
    Int J Radiat Oncol Biol Phys 70:403-12. 2008
    ..To prospectively compare the rates of pathologic response, acute toxicity, and sphincter preservation with two different schedules of preoperative chemoradiotherapy in patients with cT3 mid-distal rectal cancer...
  84. ncbi request reprint Esophageal Cancer Clinical Practice Guidelines
    Jaffer Ajani
    J Natl Compr Canc Netw 4:328-47. 2006
  85. ncbi request reprint The multidisciplinary rectal cancer treatment: main convergences, controversial aspects and investigational areas which support the need for an European Consensus
    Vincenzo Valentini
    Cattedra di Radioterapia, Universita Cattolica S Cuore, Rome, Italy
    Radiother Oncol 76:241-50. 2005
    ..Agreement between Experts, Centres, and specialists who participated in the Conference are reported...
  86. pmc Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 26:4551-6. 2008
    ..The primary end point was to assess whether any approach would achieve a >or= 77.5% 1-year survival rate, surpassing the historical 66% rate from the Radiation Therapy Oncology Group (RTOG) protocol 9405...
  87. doi request reprint The use of capecitabine in the combined-modality therapy for rectal cancer
    Stanley L Liauw
    Department of Radiation and Cellular Oncology, University of Chicago Hospitals, Chicago, IL 60637, USA
    Clin Colorectal Cancer 7:99-104. 2008
    ..This review discusses the evolution of combined-modality therapy for rectal cancer with specific attention given to the use of capecitabine in conjunction with radiation therapy...
  88. ncbi request reprint The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer
    Fabio Maria Vecchio
    Department of Pathology, Catholic University of the Sacred Heart, Rome, Italy
    Int J Radiat Oncol Biol Phys 62:752-60. 2005
    ..To examine the relationship between tumor regression grade (TRG) and outcomes in patients with rectal cancer treated with preoperative therapy...
  89. ncbi request reprint Outcome results of the 1996-1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagus
    Mohan Suntharalingam
    Department of Radiation Oncology, University of Maryland School of Medicine, 22 S Greene St, Baltimore, MD 21230 e mail
    J Clin Oncol 23:2325-31. 2005
    ..A Patterns of Care Study of patients treated from 1996 to 1999 evaluated the national practice for patients receiving radiation therapy for carcinoma of the esophagus in the United States...
  90. ncbi request reprint Chemotherapy and radiation of anal canal cancer: the first approach
    Cathy Eng
    Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Surg Oncol Clin N Am 13:309-20, viii. 2004
    ..This chapter reviews the recent literature of patients treated for squamous cell, basaloid, and cloacogenic carcinoma (collectively defined as squamous cell cancer) of the anal canal...
  91. ncbi request reprint Adjuvant management of rectal cancer: the more we learn, the less we know
    Bruce D Minsky
    J Clin Oncol 25:4339-40. 2007